Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ: CLLS )

1.480 -0.030 (-1.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 Next >
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Launch of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
From Cellectis Inc.
Via GlobeNewswire
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
From Cellectis Inc.
Via GlobeNewswire
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
From Cellectis Inc.
Via GlobeNewswire
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Third Quarter 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.